Rapamycin With Grapefruit Juice for Advanced Malignancies

Neoplasm Metastasis Clinical Trial

Official title:

A Phase Ib Study Administering Rapamycin (Sirolimus) With Grapefruit Juice in Patients With Advanced Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00375245
• Other study ID #: 14435B
• Status: Completed
• Phase: Phase 1
• First received: September 11, 2006
• Last updated: January 16, 2014
• Start date: September 2006
• Est. completion date: May 2012

Study information

• Verified date: January 2014
• Source: University of Chicago
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the highest safe dose of rapamycin when given with a fixed amount of grapefruit juice.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: May 2012
• Est. primary completion date: May 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.

• Patients with hematologic malignancies (lymphoma, multiple myeloma and chronic lymphocytic leukemia (CLL) only) are eligible to participate in the phase IB portion of the trial only.

• At least 4 weeks since prior chemotherapy or radiation therapy

• Aged 18 years or older

• ECOG performance status 0-2

• Life expectancy of greater than 3 months.

• Normal organ and marrow function:

• No transfusions of packed red blood cells within 1 week of starting treatment

• Leukocytes greater or equal to 3,000/µL

** White blood cell (WBC) greater or equal to 1,500/µL for patients with hematologic malignancies

• Absolute neutrophil count (ANC) greater or equal to 1,500/µL

** ANC greater or equal to 1,000/µL for patients with hematologic malignancies

• Platelets (PLT) greater or equal to 100,000/µL

** PLT greater or equal to 50,000/µL for patients with hematologic malignancies

• Total bilirubin within normal institutional limits

• AST (SGOT) and ALT (SGPT) less than or equal to 2.5 times institutional upper limit of normal

• Serum triglycerides less than or equal to 500 mg/dl

• Creatinine within normal institutional limits OR creatinine clearance greater or equal to 60 mL/min for patients with creatinine levels above institutional normal

• Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence)

• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.

• May not be receiving any other investigational agents.

• Uncontrolled brain metastases or malignancy. Cannot be receiving enzyme-inducing anticonvulsants.

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to rapamycin

• Gastrointestinal malabsorption syndromes, partial small bowel obstruction, or any illness that would interfere with the ability to absorb oral medications.

• Uncontrolled intercurrent illness

• Severe immunodeficient states (as judged by the treating physician)

• Pregnant women are excluded from this study; breastfeeding should be discontinued.

• HIV-positive patients receiving combination antiretroviral therapy are excluded.

• Concurrent use of ketoconazole, cyclosporine, tacrolimus, diltiazem, and rifampin with rapamycin is not permissible. The concurrent use of calcium channel blockers, terfenadine, astemizole, cisapride, propafenone, cyclosporine, midazolam, triazolam, quinidine, or theophylline with grapefruit juice is not permissible.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neoplasm Metastasis
• Tumors

Intervention

Drug:
• Rapamycin (sirolimus)
Weekly oral doses, dose is assigned at the time of study entry

Other:
• Grapefruit Juice
Daily oral doses starting during the second week on study.

Locations

Country	Name	City	State
United States	University of Chicago Hospitals	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
University of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetic interaction		4 weeks	No